Related Experiment Video
Updated: Jan 20, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Emerging Novel Therapeutics in Triple-Negative Breast Cancer
Tomas G Lyons1, Tiffany A Traina2,3
1Breast Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. lyonst@mskcc.org.
Abstract:
The mortality from breast cancer has steadily decreased due in part to early detection and advances in therapy. The treatment options for breast cancer vary considerably depending on the histological subtype. There are a number of very effective targeted therapies available for estrogen receptor-positive disease and for human epidermal growth factor receptor 2-positive disease. However, triple-negative breast cancer is a particularly aggressive subtype. This subtype represents an unmet need for improved therapies. TNBC is a heterogenous subtype of breast cancer that is beginning to be refined by its molecular characteristics and clinical response to a targeted therapeutic approach. Here we review the recent advances in the treatment of TNBC with emphasis on the many emerging novel targeted therapies.
Related Concept Videos
Emerging Adulthood
Scalar and Vector Triple Products
The scalar triple product is the dot product of a vector with the cross product of two vectors....
Negative Regulator Molecules
Introduction Cardiac Emergencies
Positive, Negative, and Zero Work
Therapeutic Index

